Aptevo held $8.3 million of cash as of September 30, 2026, versus $19.1 million of operating cash use for the nine months ended September 30, 2026, and said existing resources will not fund operations for at least one year.
APVO · Aptevo Therapeutics Inc.
Substantial doubt about the company's ability to continue as a going concern.
“When considered in aggregate, these factors raise substantial doubt about our ability to continue as a going concern for the one-year period from the date of issuance of these financial statements.”View the 10-Q filed Nov 16, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 57%
- Latest filing
- 10-Q · Nov 16
- Price history
- Mar 2020 to Nov 2026
Latest documents
Aptevo reported third-quarter 2026 results, with mipletamig achieving a 79% remission rate in high-risk TP53-mutated AML. Cash and cash equivalents were $8.3 million as of September 30, 2026, and the third-quarter net loss was $6.5 million.
Aptevo Therapeutics Inc. will ask stockholders on December 14, 2026 to authorize warrant-related issuance equal to 20% or more of outstanding Common Stock or voting power, approve a 1-for-3 to 1-for-10 reverse split, and approve its Sixth Amended and Restated 2018 Stock Incentive Plan.
Aptevo Therapeutics Inc. received approximately $3.0 million from holders exercising existing warrants covering 2,777,778 shares, then issued new warrants for 13,888,890 shares at $1.08 per share, potentially generating approximately $15.0 million.
Aptevo Therapeutics Inc. reported preclinical results from its November 7, 2026 SITC presentation: APVO451 and APVO452 activated T cells and killed cancer cells under immunosuppressive conditions, while APVO711 combined CD40 activation with PD-L1 blockade.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| evaluable frontline patients | 47 | October 2026 | — |
| evaluable TP53-mutated patients | 14 | September 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APVO
this stock
Aptevo Therapeutics Inc.
|
$1.43M | -95.6% | -74.7% | — | 2.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 37
Aptevo reported third-quarter 2026 results, with mipletamig achieving a 79% remission rate in high-risk TP53-mutated AML. Cash and cash equivalents were $8.3 million as of September 30, 2026, and the third-quarter net loss was $6.5 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APVO | -37.3% | -74.3% | -92.1% | -69.1% | -95.6% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -31.9% | -68.0% | -86.5% | -63.8% | -100.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.